Utilità del Bevacizumab nell'evoluzione della retinopatia diabetica

Aim of the study: Evaluation of the therapeutic efficacy of Bevacizumab in the treatment of diabetic macular oedema. Design: retrospective case series. Materials and Methods: 20 eyes of 17 patients with diabetic macular oedema underwent a cycle of 3 intravitreal injections (each dose: 1,25 mg of Bevacizumab), with an interval of a month between each other. Patients were controlled the following day, 20 days after each injection and at three months after the third injection. During the controls, visual acuity (BCVA) and central macular thickness using the OCT were determined. Results: The mean value of BVCA at baseline was 0,79±0,49 logMAR. After the first injection was 0,74±0,49 log¬MAR, with a further increase after the second administration (0,66±0,49 logMAR p=0,02). After the third injection was noted a small reduction of BCVA (0,69±0,45 logMAR p=0,036), in spite of this, its value was better than the one at baseline. At the end of the cycle, the final result included: 10 eyes (50%) with an improvement of visual acuity, 8 eyes (40%) that remained stable and 2 eyes (10%) with a reduction of visual acuity compared to baseline. The average value of macular thickness, at the last control, was lowered about 73 µm in comparison with the baseline. Conclusions: Although therapeutic efficacy of Bevacizumab was evident after the first injection, a repeated treat¬ment seems to prolong its beneficial effect, because it prevents a reduction of intravitreal concentrations.